Low Neurophysiologic Resistance to Anesthetics as a Marker of Preclinical/Prodromal Alzheimer's Disease and Neurovascular Pathology, Delirium risk and Inattention

总结 在R 01研究项目中，题为“麻醉剂的低神经生理学抗性作为 临床前/前驱阿尔茨海默病和神经血管病理学，谵妄风险和注意力不集中，”我们是 检查是否-大脑中神经退行性疾病类型的变化 结构和活动，使患者易于显示对麻醉药物反应的改变的脑活动变化 在手术期间提供。这个R 01项目利用了改变大脑活动的想法， 药物反映了一个不健康的大脑，这可能有潜在的迹象，临床前AD，这可能表明， 增加POD的风险。R 01项目的预期结果是更好地理解 术中脑脑电图对麻醉药物的反应，术后谵妄，阿尔茨海默病 和相关的痴呆症，以及这些实体之间的关系。 在本行政补充申请中，我们建议研究临床前/ 前驱路易体痴呆（LBD）病理学（即称为α突触核蛋白的蛋白质的改变形式） .已经很好地确定，患有谵妄和 痴呆在前α/θ频率和总的主频率中显示出相似的EEG异常， 类似于LBD患者。因此，麻醉期间的EEG活动模式可能能够作为 指标-突触核蛋白水平，这可能有助于识别风险患者，以进一步检查LBD，AD， 和其他相关痴呆症。

SUMMARY In the parent R01 research project entitled "Low Neurophysiologic Resistance to Anesthetics as a Marker of Preclinical/Prodromal Alzheimer's Disease and Neurovascular Pathology, Delirium risk and Inattention," we are examining whether - neurodegenerative disease-type changes in brain structure and activity, predispose patients to show altered brain activity changes in response to anesthetic drugs provided during surgery. This R01 project exploits the idea that altered brain activity in response to anesthetic drugs reflects an unhealthy brain, which may have latent signs of pre-clinical AD and which may indicate an increased risk of POD. The expected outcome of the R01 project is to understand better the mechanisms underlying intraoperative brain EEG responses to anesthetic drugs, postoperative delirium, Alzheimer s Disease and related dementias, and relationships between these entities. In this Administrative Supplement application, we propose to investigate the relationship between preclinical/ prodromal Lewy body dementia (LBD) pathology (ie altered forms of a protein called alpha synuclein) . It has been well established that patients with delirium and dementia display similar EEG abnormalities in pre-alpha/theta frequencies and dominant frequency overall, similar to patients with LBD. Thus, EEG activity patterns during anesthesia may be able to serve as an indicator -Synuclein levels, which might help to identify at risk patients for further workup for LBD, AD, and other related dementias.2-4